|
|
|
|
| Join Drug Delivery Leader Live in discussing human factors risk analysis approaches for combination products and medical devices. Central to the conversation will be the FDA’s draft guidance on Use-Related Risk Analysis (URRA) and how this guidance is related to other risk tools, such as a use Failure Mode and Effects Analysis (uFMEA). Secure your spot for this free digital event happening November 13th. |
|
|
|
|
By Drug Delivery Leader: Sit and Deliver | Dr. Stephen Marcus boasts drug development experience across various routes of administration targeting varied therapeutic areas. Now as Cantex CEO, he leans on his background as an oncologist to drive his passion for effectively treating cancer while easing the patient experience. In this episode of Sit and Deliver, host Tom von Gunden asks Dr. Marcus about innovations in small molecule delivery for complex, life-threatening conditions. |
|
|
|
| Compliance Considerations For Emergency-Use Delivery Systems | Article | By Richard Motruk and Nathan Blazei, Kymanox Corporation | Because auto-injectors are typically the delivery device of choice for emergency medications, they come with increased scrutiny from regulatory bodies regarding their safety and effectiveness. |
|
|
| Imaging Large Volume Subcutaneous Injections To Inform Clinical Design | Poster | By Natasha G. Bolick, Wendy D. Woodley, Suvadra S. Gerth, Douglas B. Sherman, Ph.D., et al., BD Medical - Pharmaceutical Systems | New higher volume, higher viscosity pharmaceutical formulations for subcutaneous injection, alternatives to traditional intravenous treatment, enable chronic disease therapy in alternate settings. |
|
|
|
| Advances In Oral GLP-1 Analogs For Obesity | Webinar | Adare Pharma Solutions | Discover how these groundbreaking Oral GLP-1 Analogs therapies are reshaping obesity management and addressing key challenges in formulation and delivery. |
|
|
|
|
|
|
|
|
|
.png){kind=logo}
